Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS)

Please see the May 2012 FDA safety communication concerning Gilenya

Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS).

It's a new immune modulator that prevents some white blood cells from migrating to the CNS and damaging it.

Gilenya is approved for first-line use...but don't expect it to replace beta-interferons (Avonex, etc), or Copaxone (glatiramer). These drugs have a longer safety record and they're less expensive.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote